Project Grant R21CA307898
Award Date 7/13/26
Completion Date 6/30/28
Dollars Obligated $417K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Colorado-Denver $584,510 under the Cancer Biology Research program (CFDA 93.396) on September 12, 2025, with completion scheduled for August 31, 2029. This Project Grant supports the continued development and implementation of advanced spatial transcriptomics and proteomics technologies within the Human Immune Monitoring Shared Resource (HIMSR), a core facility of the University of Colorado Cancer Center...
- Federal Grant Award Summary The University of Colorado-Denver received a $547,080 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 17, 2025, with an ultimate completion date of August 31, 2029. This award supports the University of Colorado Cancer Center's (UCCC) initiative to advance cancer screening and prevention trials through enhanced clinical trial accrual and increased diversity in participant enrollment....
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Colorado-Denver $491,315 under the Cancer Biology Research program (CFDA 93.396) on September 12, 2025, with a completion date of August 31, 2029. This Project Grant supports the Functional Genomics Shared Resource (FGSR) at the University of Colorado Cancer Center, directed by Dr. Molishree Joshi, which provides advanced functional genomics technologies and services to academic research laboratories. The...
- Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $625,470 to The Regents of the University of Colorado (University of Colorado-Denver) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026 through April 30, 2031. The award supports research into novel dietary interventions targeting endocrine therapy resistance (ETR) in estrogen receptor (ER)-positive breast cancer. The project investigates how...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a Project Grant of $770,666 to the University of Colorado's Office of Contracts and Grants (awarded March 19, 2026; completion February 28, 2028) to conduct fundamental research on splicing-mediated dysregulation of interferon signaling in cancer. The project investigates how transposon-derived exonization creates altered protein isoforms of the IFNAR2 gene that...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $156,000 through its Cancer Biology Research program (CFDA 93.396) to the University of Colorado–Denver for a two-year project (April 1, 2026–March 31, 2028) focused on optimizing pre-clinical models of adamantinomatous craniopharyngioma (ACP), a rare and highly morbid pediatric brain tumor. The project addresses critical gaps in available research tools by refining and validating patient-derived organoid (PDO) and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $246,362 to the Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) on June 12, 2026, with a completion date of May 31, 2031. This Project Grant funds research to elucidate the mechanisms by which homologous recombination deficiency (HRD), particularly BRCA2 mutations, affects estrogen receptor-positive (ER+) breast cancer responsiveness to endocrine therapy. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute, under its Cancer Treatment Research program (CFDA 93.395), awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 effective June 1, 2026, with completion targeted for May 31, 2028. This award supports research into fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project leverages...
- Grant Award Summary The National Cancer Institute (NCI) awarded $545,195 to the University of Arizona under the Cancer Biology Research program (CFDA 93.396) on July 10, 2026, for a five-year project extending through June 30, 2031. The project, "Interrogating Niche-Specific Nuclear and Extra-Nuclear Estrogen Receptor-Alpha (ER) Signaling to Prevent ER+ Breast Cancer Progression in ER+ Bone," investigates mechanisms by which estrogen receptor signaling drives estrogen receptor-positive...